Boehringer Ingelheim and Zealand Pharma receive FDA fast track designation for investigational treatment for NASH

Boehringer Ingelheim

2 June 2021 - FDA’s fast track designation for the GLP-1/glucagon dual agonist underscores the urgent need for new treatment options to fulfil the unmet medical needs of people affected by non-alcoholic steatohepatitis.

Boehringer Ingelheim and Zealand Pharma today announced that the US FDA has granted fast track designation to the GLP-1/glucagon dual agonist BI 456906 for adults with non-alcoholic steatohepatitis.

Read Boehringer Ingelheim press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Medicine , US , Fast track